# Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures

> **NCT02389621** · PHASE3 · COMPLETED · sponsor: **Shionogi** · enrollment: 215 (actual)

## Conditions studied

- Chronic Liver Disease
- Thrombocytopenia

## Interventions

- **DRUG:** Lusutrombopag
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02389621
- **Lead sponsor:** Shionogi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-15
- **Primary completion:** 2017-04-05
- **Final completion:** 2017-04-19
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2018-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02389621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02389621, "Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02389621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*